SG11201407682TA - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorsInfo
- Publication number
- SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- receptor modulators
- glucocorticoid receptor
- heteroaryl
- fused azadecalin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261651669P | 2012-05-25 | 2012-05-25 | |
US201261691083P | 2012-08-20 | 2012-08-20 | |
US201261715907P | 2012-10-19 | 2012-10-19 | |
US201361759520P | 2013-02-01 | 2013-02-01 | |
US201361781629P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/042732 WO2013177559A2 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407682TA true SG11201407682TA (en) | 2014-12-30 |
Family
ID=49624542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407682TA SG11201407682TA (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Country Status (22)
Country | Link |
---|---|
EP (5) | EP3851107B1 (pt) |
JP (1) | JP6172871B2 (pt) |
KR (1) | KR102062640B1 (pt) |
CN (1) | CN104619328B (pt) |
AU (1) | AU2013266110C1 (pt) |
CA (1) | CA2872260C (pt) |
CL (1) | CL2014003173A1 (pt) |
DK (4) | DK2854814T3 (pt) |
ES (4) | ES2665338T3 (pt) |
HK (2) | HK1208818A1 (pt) |
IL (1) | IL235868A (pt) |
MX (1) | MX365423B (pt) |
MY (1) | MY172739A (pt) |
NZ (1) | NZ701469A (pt) |
PE (1) | PE20150352A1 (pt) |
PH (1) | PH12014502584A1 (pt) |
PL (4) | PL3590517T3 (pt) |
PT (4) | PT2854814T (pt) |
RU (1) | RU2639867C2 (pt) |
SG (1) | SG11201407682TA (pt) |
WO (1) | WO2013177559A2 (pt) |
ZA (1) | ZA201408182B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
DK3074011T3 (da) | 2013-11-25 | 2019-09-30 | Corcept Therapeutics Inc | Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer |
CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
EP3277281B1 (en) * | 2015-03-30 | 2022-01-05 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
KR20180008627A (ko) * | 2015-05-18 | 2018-01-24 | 코어셉트 쎄라퓨틱스, 잉크. | 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 |
WO2017027851A1 (en) * | 2015-08-13 | 2017-02-16 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
KR20180116372A (ko) * | 2016-03-01 | 2018-10-24 | 코어셉트 쎄라퓨틱스, 잉크. | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
AU2018244928B2 (en) * | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
EP3641780A4 (en) * | 2017-06-20 | 2021-02-24 | Corcept Therapeutics, Inc. | TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
AU2019261274B2 (en) * | 2018-04-23 | 2021-10-28 | Corcept Therapeutics, Inc. | Methods of preparing regioselective N-alkyl triazoles |
KR102651146B1 (ko) * | 2018-11-09 | 2024-03-25 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 뇌하수체 종양을 축소시키는 방법 |
EP3897589A4 (en) * | 2018-12-19 | 2022-10-12 | Corcept Therapeutics Incorporated | PHARMACEUTICAL FORMULATIONS CONTAINING A RELACORILANT, AN AZADECALIN COMPOUND FUSED WITH A HETEROARYL KETONE |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
CA3122581A1 (en) | 2018-12-20 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods for imaging and treatment of somatostatin-receptor positive tumors |
WO2020172501A1 (en) | 2019-02-22 | 2020-08-27 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
AU2020367769B2 (en) * | 2019-10-16 | 2023-10-12 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
JP2023505948A (ja) | 2019-12-11 | 2023-02-14 | コーセプト セラピューティクス, インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
WO2021127376A1 (en) * | 2019-12-21 | 2021-06-24 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
CN116829556A (zh) * | 2021-02-03 | 2023-09-29 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
DK1735308T3 (da) * | 2004-03-09 | 2009-01-19 | Corcept Therapeutics Inc | Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer |
US7640389B2 (en) * | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
SG187909A1 (en) * | 2010-08-27 | 2013-03-28 | Corcept Therapeutics Inc | Pyridyl-amine fused azadecalin modulators |
-
2013
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en active Application Filing
- 2013-05-24 EP EP22193438.3A patent/EP4119561A1/en active Pending
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active IP Right Grant
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584A1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2015
- 2015-09-29 HK HK15109587.3A patent/HK1208818A1/xx unknown
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201808729WA (en) | Bet protein degraders | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201408261UA (en) | Syringe | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |